b
r
c
histor
diagnosi
enigmat
pulmonari
diseas
hematopoiet
cell
transplant
hct
requir
lung
biopsi
recent
advanc
diagnosi
therapi
respiratori
infect
chang
clinician
approach
pulmonari
abnorm
examin
tempor
trend
use
lung
biopsi
hct
retrospect
review
patient
underw
first
allogen
hct
fred
hutchinson
cancer
research
center
year
subsequ
underw
surgic
lung
biopsi
reason
lung
biopsi
cohort
analyz
use
cox
proport
hazard
model
death
relaps
consid
compet
risk
patient
underw
posthct
surgic
lung
biopsi
compar
biopsi
cohort
case
surgic
lung
biopsi
hct
recipi
occur
cohort
median
time
biopsi
posthct
day
iqr
earli
cohort
day
iqr
late
cohort
overal
biopsi
incid
per
patient
day
first
year
hct
respect
patient
cohort
less
like
undergo
lung
biopsi
adjust
hr
ci
p
compar
patient
earli
cohort
patient
earli
cohort
underw
lung
biopsi
without
anteced
bronchoscopi
versu
p
although
infect
common
find
biopsi
earli
cohort
versu
p
number
biopsi
demonstr
noninfecti
lesion
similar
two
cohort
versu
p
fungal
infect
major
infecti
etiolog
cohort
versu
p
signific
reduct
number
aspergillu
speci
found
biopsi
cohort
versu
p
similar
percentag
underw
biopsi
therapeut
intent
invas
fungal
diseas
cohort
versu
surgic
evalu
lung
diseas
hct
recipi
significantli
declin
span
decad
declin
year
compar
reduct
number
biopsi
posttranspl
infect
due
aspergillosi
tempor
relat
improv
diagnost
test
minim
invas
mean
increas
use
empir
therapi
extendedspectrum
azol
practic
primari
nonsurg
diagnost
treatment
approach
pulmonari
diseas
posthct
continu
shown
low
number
surgic
biopsi
last
year
pulmonari
complic
frequent
encount
patient
undergo
hematopoiet
cell
transplant
hct
due
varieti
infecti
noninfecti
etiolog
mani
indistinguish
either
symptom
radiolog
imag
treatment
option
vari
wide
misdiagnosi
lead
inappropri
therapi
compromis
recoveri
lead
excess
morbid
mortal
aggress
diagnost
approach
essenti
accur
identif
pulmonari
complic
highrisk
patient
histor
diagnost
approach
enigmat
lung
diseas
hct
often
led
surgic
lung
biopsi
surgic
lung
biopsi
advantag
diagnost
well
therapeut
instanc
particularli
focal
invas
fungal
infect
howev
improv
noninvas
diagnost
modal
infect
allow
earli
diagnosi
detect
less
invas
fiberopt
bronchoscopi
thu
obviat
need
surgeri
emerg
broadspectrum
triazol
antifung
liposomallipid
complex
polyen
earli
allow
increas
use
less
toxic
empir
therapi
patient
presum
fungal
infect
limit
necess
anteced
lung
biopsi
still
mani
situat
diagnosi
remain
uncertain
lung
biopsi
remain
gold
standard
achiev
diagnosi
purpos
studi
examin
tempor
trend
use
surgic
lung
biopsi
hct
patient
relat
emerg
improv
diagnost
therapeut
strategi
invas
fungal
diseas
addit
examin
diagnost
outcom
util
lung
biopsi
relationship
bronchoscopi
consid
time
period
routin
use
efficaci
broadspectrum
triazol
antifung
regimen
final
propos
potenti
strategi
diagnost
workup
decisionmak
appropri
use
surgic
lung
biopsi
hct
review
data
patient
receiv
first
allogen
hct
fred
hutchinson
cancer
research
center
fhcrc
year
earli
cohort
late
cohort
third
cohort
year
current
cohort
also
review
recipi
underw
surgic
lung
biopsi
within
year
day
hct
identifi
prospect
collect
databas
allogen
transplant
patient
previous
describ
addit
case
also
identifi
patholog
record
confirm
chart
review
case
incomplet
clinic
biopsi
data
institut
exclud
analysi
studi
protocol
approv
institut
review
board
fhcrc
patient
receiv
condit
regimen
follow
infus
donor
cell
determin
transplant
team
transplant
patient
receiv
immunosuppress
agent
prophylaxi
graftversushost
diseas
posttranspl
period
standard
infecti
prophylaxi
includ
acyclovir
herp
simplex
viru
varicella
zoster
viru
trimethoprimsulfamethoxazol
atavoquon
dapson
pneumocysti
jirovecii
fungal
prophylaxi
fluconazol
patient
receiv
either
ceftazidim
levofloxacin
neutropen
prophylaxi
later
cohort
patient
proven
probabl
fungal
infect
pulmonari
nodul
like
get
extendedspectrum
azol
voriconazol
posaconazol
patient
cytomegaloviru
cmv
infect
basi
antigen
dna
test
given
preemptiv
therapi
ganciclovir
foscarnet
patient
develop
respiratori
symptom
hct
underw
diagnost
test
includ
imag
studi
chest
radiograph
andor
comput
tomographi
chest
laboratori
test
empir
treatment
order
discret
primari
servic
subsequ
decis
invas
diagnost
workup
includ
bronchoaveolar
lavag
bal
fine
needl
aspir
fna
andor
surgic
lung
biopsi
made
consult
pulmonari
infecti
diseas
thorac
surgeri
servic
bal
perform
sampl
test
evid
specif
pathogen
list
tabl
specimen
also
underw
cytopatholog
review
pathologist
center
patholog
diagnos
categor
main
categori
infecti
noninfecti
nondiagnost
biopsi
consid
nondiagnost
patholog
find
nonspecif
sampl
insuffici
diagnosi
anteced
bronchoscopi
bal
defin
bronchoscopi
perform
intent
diagnosi
pulmonari
condit
ultim
diagnos
treat
surgic
biopsi
surgic
biopsi
radiolog
report
categor
specif
find
seen
comput
tomographi
modifi
previous
publish
definit
focal
lesion
includ
solitari
pulmonari
nodul
mass
consolid
multifoc
infiltr
mass
consolid
diffus
includ
diffus
ground
glass
opac
andor
nodular
ground
glass
opac
lung
involv
outcom
data
analyz
use
fisher
exact
test
categor
variabl
wilcoxon
ranksum
continu
variabl
incid
surgic
biopsi
calcul
number
biopsi
perform
per
cohort
per
total
number
patient
day
risk
within
year
causespecif
hazard
lung
biopsi
within
year
compar
cohort
use
cox
proport
hazard
model
death
relaps
consid
compet
risk
adjust
patient
age
sever
diseas
low
intermedi
high
donor
type
statist
softwar
use
sa
version
sa
institut
cari
nc
earli
cohort
chartverifi
lung
biopsi
perform
first
allogen
hct
recipi
fhcrc
biopsi
occur
posthct
compris
surgic
lung
biopsi
fna
among
patient
tabl
overal
surgic
lung
biopsi
incid
within
first
year
hct
per
patient
day
respect
earli
late
cohort
patient
late
cohort
less
like
undergo
lung
biopsi
unadjust
hazard
ratio
confid
interv
p
adjust
hazard
ratio
confid
interv
p
compar
patient
earli
cohort
median
time
biopsi
posthct
day
interquartil
rang
infect
like
found
biopsi
earli
cohort
compar
late
cohort
versu
p
figur
infecti
diagnos
cohort
versu
p
attribut
fungal
infect
howev
aspergillu
speci
common
earli
cohort
account
fungal
infect
late
cohort
tabl
reduct
number
aspergillu
speci
found
biopsi
cohort
signific
versu
p
biopsi
demonstr
fungal
infect
mucoral
speci
frequent
seen
late
cohort
versu
one
addit
fungal
infect
caus
p
jirovecii
detect
biopsi
p
howev
overal
number
biopsi
demonstr
noninfecti
etiolog
similar
cohort
versu
p
cohort
common
specif
noninfecti
diagnosi
bronchiol
obliteran
organ
pneumoniacryptogen
organ
pneumonia
earli
n
late
n
specif
diagnos
includ
diffus
alveolar
hemorrhag
interstiti
pneumonia
oblit
bronchiol
two
biopsi
earli
cohort
late
cohort
reveal
concurr
infecti
noninfecti
diagnos
tabl
remaind
consist
nonspecif
histolog
diffus
alveolar
damag
bronchiti
bronchiol
normal
lung
earli
n
late
n
note
earli
cohort
fna
perform
posthct
recipi
nondiagnost
patient
nondiagnost
fna
follow
surgic
biopsi
achiev
specif
diagnosi
late
cohort
fna
surgic
biopsi
pursu
nondiagnost
fna
achiev
specif
diagnosi
remain
specif
diagnos
includ
stenotrophomona
maltophilia
paenibacillu
speci
carcinoid
case
mucoral
infect
follow
therapeut
surgic
resect
biopsi
earli
cohort
perform
focal
lesion
wherea
biopsi
later
cohort
perform
patient
multifoc
diffus
diseas
instanc
surgic
procedur
perform
therapeut
intent
invas
fungal
diseas
diagnosi
establish
bronchoscopi
fna
prior
surgic
biopsi
similar
number
biopsi
done
therapeut
intent
cohort
versu
late
cohort
surgic
resect
perform
known
aspergillosi
remain
diseas
due
mucoral
speci
previous
diagnos
method
fna
note
advanc
care
hct
recipi
area
support
care
diagnost
test
infecti
prophylaxi
result
improv
surviv
past
year
concord
use
less
toxic
condit
regimen
better
longterm
outcom
grow
percept
scope
pulmonari
diseas
shift
acut
diseas
earli
posttranspl
cours
increas
late
noninfecti
pulmonari
complic
implement
rapid
detect
cmv
bal
fluid
preemptiv
treatment
strategi
ganciclovir
foscarnet
led
declin
incid
mortal
cmv
pneumonia
addit
major
shift
antifung
treatment
prevent
improv
outcom
accordingli
postul
clinic
practic
diagnosi
hctrelat
pulmonari
diseas
evolv
tandem
recent
improv
diagnost
technolog
treatment
aim
major
pulmonari
infect
examin
practic
shed
light
optim
standard
care
clinic
practic
contemporari
era
hct
span
institut
surgic
lung
biopsi
significantli
declin
incid
tend
occur
later
hct
associ
declin
biopsyproven
specif
diagnos
infecti
etiolog
addit
although
correspond
increas
proport
noninfecti
etiolog
diagnos
lung
biopsi
overal
number
case
rel
total
number
patient
risk
chang
low
number
surgic
biopsi
transplant
past
year
suggest
reduct
need
surgic
diagnosi
earli
cohort
aspergillosi
common
infecti
diagnosi
well
common
diagnos
overal
posttranspl
consist
welldocu
observ
aspergillosi
common
pulmonari
fungal
infect
affect
hct
patient
focal
lung
lesion
persist
despit
antibiot
therapi
usual
fungal
declin
appear
driven
almost
entir
drop
aspergillusrel
lung
biopsi
diagnos
addit
shift
perform
biopsi
radiograph
multifoc
diffus
diseas
often
link
primarili
noninfecti
diagnos
diffus
infiltr
hct
histor
associ
cmv
pneumon
diagnosi
rare
identifi
lung
biopsi
confirm
data
declin
frequenc
lung
biopsi
like
relat
tempor
improv
therapeut
diagnost
strategi
invas
aspergillosi
supplementari
figur
thirdgener
triazol
antifung
agent
voriconazol
approv
clinic
use
subsequ
becom
firstlin
treatment
invas
aspergillosi
toler
oral
bioavail
data
suggest
enhanc
efficaci
improv
toxic
profil
compar
amphotericin
b
agent
class
specif
posaconazol
isavuconazol
expand
option
empir
use
voriconazol
suspici
radiograph
lesion
becom
wide
accept
practic
like
increas
use
agent
directli
relat
decreas
number
biopsi
perform
diagnosi
platelia
sandwich
elisa
biorad
hercul
ca
galactomannan
commerci
avail
unit
state
sinc
rapid
noninvas
diagnosi
invas
aspergillosi
detect
galactomannan
bal
fluid
highli
sensit
hct
recipi
sensit
serum
galactomannan
particularli
neutropen
patient
togeth
serum
bal
galactomannan
diagnos
increas
abil
identifi
aspergillu
allow
patient
receiv
highli
effect
therapi
assay
advanc
microbiolog
diagnost
eg
pcr
test
bronchoscopi
supplant
surgic
lung
biopsi
firstlin
invas
diagnost
procedur
evalu
pulmonari
lesion
hct
recipi
earli
diagnost
bronchoscopi
recommend
empir
treatment
hct
recipi
evid
specif
pulmonari
process
like
higher
yield
clinic
suspicion
infect
high
shift
practic
illustr
increas
proport
lung
biopsi
recipi
underw
anteced
bronchoscopi
bal
late
cohort
compar
earli
cohort
consequ
cohort
patient
underw
surgic
lung
biopsi
perform
latter
cohort
like
highli
select
group
empir
therapi
antiinfect
agent
improv
infiltr
bronchoscopi
yield
diagnosi
surgeri
perform
therapeut
intent
surgic
procedur
fungal
diseas
perform
therapi
establish
mucoral
spp
infect
common
invas
fungal
diseas
late
cohort
epidemiolog
consist
use
empir
voriconazol
compar
earli
cohort
given
mucoral
spp
suscept
voriconazol
although
number
biopsi
identifi
specif
etiolog
identif
specif
diagnos
treatment
cryptogen
organ
pneumonia
suggest
surgic
lung
biopsi
use
patient
fail
prophylaxi
empir
therapi
infect
neg
bal
evalu
rariti
lung
biopsi
current
cohort
suggest
bal
identifi
infecti
etiolog
may
suffici
clinician
begin
empir
therapi
presumpt
infect
noninfecti
pulmonari
complic
note
transbronchi
biopsi
posthct
time
frame
cohort
center
transbronchi
biopsi
rare
perform
hct
recipi
transbronchi
biopsi
lead
complic
uniqu
diagnos
bal
nondiagnost
although
analysi
incid
posthct
noninfecti
pneumonia
beyond
scope
studi
like
collect
experi
typic
radiograph
featur
cryptogen
organ
pneumonia
hct
appropri
clinic
set
absenc
infect
obviat
need
surgic
lung
biopsi
howev
radiograph
featur
uncharacterist
organ
pneumonia
potenti
complic
corticosteroid
outweigh
benefit
empir
treatment
surgic
lung
biopsi
may
still
requir
establish
firm
diagnosi
although
detail
analysi
fna
minim
invas
altern
surgeri
obtain
tissu
aim
studi
worth
note
overal
use
modal
low
cohort
fna
shown
rel
high
yield
hct
recipi
specif
aspergillosi
particularli
peripher
focal
lesion
howev
systemat
analysi
modal
perform
sinc
introduct
broadspectrum
triazol
galactomannan
test
decis
refer
patient
fna
like
due
number
factor
vari
institut
institut
includ
avail
intervent
radiolog
locat
specif
lesion
clinician
bia
regard
risktobenefit
ratio
particularli
set
thrombocytopenia
small
number
fna
may
also
reflect
declin
case
aspergillosi
number
case
cohort
small
draw
specif
conclus
util
fna
like
highest
yield
lesion
focal
peripher
suffici
size
obtain
adequ
materi
patholog
microbiolog
cultur
valu
surgic
lung
biopsi
highest
benefit
achiev
specif
diagnosi
outweigh
surgic
risk
popul
surgeri
potenti
therapeut
case
suspect
invas
fungal
infect
unrespons
standard
therapi
distinguish
infecti
noninfecti
etiolog
empir
therapi
fail
critic
step
decid
whether
continu
withhold
chang
therapi
particularli
nonaspergillu
mold
speci
suspect
videoassist
thoracoscop
surgeri
introduc
earli
reduc
morbid
associ
open
lung
biopsi
accept
wide
use
diagnost
therapeut
purpos
situat
clinic
judgment
equivoc
less
invas
mean
uninform
surgic
biopsi
consid
propos
algorithm
aid
workup
pulmonari
abnorm
hct
shown
figur
reflect
current
practic
institut
consist
studi
investig
yield
bal
lung
biopsi
popul
although
algorithm
base
radiograph
pattern
clinic
context
clinic
suspicion
specif
diagnosi
clinic
feasibl
perform
bronchoscopi
ie
patient
characterist
locat
size
lesion
dictat
diagnost
workup
andor
empir
manag
voriconazol
gener
chosen
firstlin
empir
therapi
case
pulmonari
nodul
frequenc
aspergillosi
avail
eas
administr
drug
newer
tablet
formul
posaconazol
improv
bioavail
activ
mucoral
spp
may
also
consid
option
empir
therapi
studi
limit
singlecent
retrospect
design
diagnost
practic
evalu
lung
diseas
use
empir
antifung
pulmonari
nodul
vari
institut
institut
given
avail
specif
test
frequenc
bronchoscopi
medic
practition
experi
perform
lung
biopsi
special
popul
immunocompromis
patient
studi
reflect
larg
academ
center
highvolum
hct
practic
pulmonari
servic
experi
bal
hct
avail
centerspecif
microbiolog
test
fungal
pcr
util
surgic
lung
biopsi
observ
studi
may
applic
clinic
practic
set
experi
hct
limit
surgic
lung
biopsi
may
primari
mean
achiev
diagnosi
addit
diagnost
algorithm
present
must
also
taken
context
local
diagnost
test
option
geograph
fungal
epidemiolog
pattern
case
endpoint
rest
clinic
decis
result
may
simpli
base
bias
physician
group
physician
encount
patient
summari
diagnost
practic
lung
diseas
evolv
reflect
chang
epidemiolog
opportunist
infect
hct
well
collect
experi
empir
manag
noninfecti
complic
consequ
improv
outcom
aspergillosi
burden
pulmonari
patholog
shift
late
noninfecti
complic
area
unmet
need
popul
addit
nodul
due
invas
fungal
diseas
unrespons
empir
therapi
larg
caus
nonaspergillu
speci
observ
suggest
need
investig
minim
invas
mean
diagnos
noninfecti
pulmonari
complic
improv
diagnost
tool
efficaci
treatment
import
late
pulmonari
complic
hct
